BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 21, 2018
View Archived Issues
Adipose-derived regenerative cell therapy safe in patients with erectile dysfunction
Read More
Polymorphisms in miRNA-146a and IRAK1 are associated with susceptibility to SLE and MS
Read More
Harbour BioMed licenses ex-China rights to Kelun-Biotech's A-167
Read More
Common pathway may underlie schizophrenia and PD
Read More
Getting at stored mRNAs part of fragile X problem
Read More
HDAC inhibitors optimized for CNS drug-like properties and hematological safety
Read More
Phase Ib data guide Novan's development of SB-414 for atopic dermatitis
Read More
New oral selective apelin agonist AM-2995 developed for heart disease treatment
Read More
Chugai's describes candidate for the treatment of hyperphosphatemia EOS-798
Read More
Novo Nordisk reports topline PIONEER 5 results for oral semaglutide
Read More
Phase III study of MC2-01 cream in psoriasis vulgaris meets primary and secondary endpoints
Read More
Biogen identifies new NRF2 activators
Read More
Adare Pharmaceuticals describes cysteamine prodrugs
Read More
Antiangiogenic compounds synthesized at Celgene
Read More
Vectura completes pediatric studies with VR-647 for asthma
Read More
Hanmi Science patents oncolytic compounds
Read More
New Rho kinase inhibitors described by Chiesi Farmaceutici
Read More
Japanese approval for Tagrisso as first-line treatment of EGFR-mutated NSCLC
Read More
Phase II trial of TLC-599 for osteoarthritis pain meets primary and key secondary endpoints
Read More
FDA approves expanded label for Keytruda for first-line treatment of metastatic non-squamous NSCLC
Read More
Ascentage Pharma opens phase I trial of APG-2575 in hematologic malignancies
Read More